Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 ...

Fidelity Select Biotechnology Portfolio earns an Above Average Process Pillar rating. The main driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...